Biotech Stock Roundup: Sophiris amp; Cyclacel Plunge on Data, ChemoCentryx ...
An early look at the data from the study evaluating PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia showed that a predefined efficacy threshold was not met. This is highly disappointing news for the company and ...
Zacks.com - Wed, 17 Dec 2014 06:26

Sophiris's PRX302 Misses Efficacy Threshold In Interim Readout (SPHS)
Sophiris announced on December 15th that the company's treatment for benign prostate hyperplasia called PRX-302 did not meet the predefined efficacy threshold at the three-month interim readout. Given the company will be initiating a phase 2a trial in ...
Seeking Alpha - Wed, 17 Dec 2014 06:15



Ten Bonus Health Benefits of Birth Control
Endometrial Cancer – In a healthy woman, the uterine lining thickens and then thins each month unless she gets pregnant, but sometimes this cycle breaks down, creating a condition called hyperplasia in which the cells build up. This can be a sign of ...
Institute for Ethics and Emerging Technologies - Mon, 15 Dec 2014 18:03

Porter Regional Hospital Presents Community Wellness Events for January 2015
Join Urologist Dr. Kparker to learn what good prostate health involves as well as how to maintain a healthy prostate and deal one of the most common problems, benign prostatic hyperplasia (BPH) or an enlarged prostate gland. The event will be held at 6 ...
PortageLife - Wed, 17 Dec 2014 08:07

Sophiris Plunges on Disappointing Data on its BPH Candidate
... Report) shares plummeted 81.5% after the company announced disappointing data from an interim efficacy analysis of its ongoing phase III PLUS-1 study on PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH).
Zacks.com - Tue, 16 Dec 2014 12:26

Pfizer Moving Into Gene Therapy Is A Welcome Move
... estrogen agonist/antagonist (also known as a selective estrogen receptor modulator). The drug has the advantage of protecting uterus lining against hyperplasia, which increases risk of cancer of uterine lining and can happen with estrogen-only ...
Nasdaq - Tue, 16 Dec 2014 08:52

Genetic risks depends on parents' test results
Dear Dr. Roach • I am a 27-year-old woman with three sisters. Recently, our mother had a mammogram and a spot was found. After a biopsy, it was determined to be atypical hyperplasia. They removed all affected tissue but told my mother that she does ...
STLtoday.com - Thu, 11 Dec 2014 22:00

The Zacks Analyst Blog Highlights: Sophiris, ChemoCentryx, Exelixis, Roche ...
An early look at the data from the study evaluating PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia showed that a predefined efficacy threshold was not met. This is highly disappointing news for the company and ...
SYS-CON Media (press release) - Thu, 18 Dec 2014 06:35


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014